new glp-1 drugs in development What is the pipeline for future medications for obesity? GLP-1 Drugs Market Size to
Description
Chest 141(2 Suppl):e44Se88S Witt DM, Clark NP, Kaatz S, Schnurr T, Ansell JE (2016) Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism
In recent years, glucagon-like peptide-1 (GLP-1) receptor agonists have been used to control blood glucose levels in patients with diabetes
There was no plateau in weight loss at 46 weeks with the potential of further weight loss over a longer time period
[DOI] [PMC free article] [PubMed] [Google Scholar] 38.Nanus DE, Filer AD, Hughes B, Fisher BA, Taylor PC, Stewart PM, Buckley CD, McInnes I, Cooper MS, Raza K
13 The median expected protection we determined for GLP-1 receptor agonistswhich exceeds 18 yearsis the highest yet reported for drug-device combinations
( 13 ) Liraglutide is sometimes preferred for patients who cannot tolerate newer GLP-1s or who have insurance coverage that favors it
